Cardiovascular Safety in Drug Development: QT, Arrhythmias, Thrombosis, and Bleeding

Event

Begins

April 11, 2010

Ends	April 13, 2010

Papers

Ab.

Country

USA

State

City

Arlington

Category

Health: Pharmacy

Category 2

Category 3

Exhibits

Organization

Contact

URL

http://

Venue

Sheraton National Hotel Arlington

Description

Abstract Submission Guidelines

Please submit all abstracts via email to Rachel Minnick, Program Developer Rachel.Minnick@diahome.org

All abstracts must be received by February 13, 2010

Authors of selected abstracts will be notified by March 13, 2010

Suggested Abstract Topics

(The strongest abstracts have been those with a clear hypothesis and supporting data with a strong scientific design)

Drug Development and CV safety

· Drug-induced increases in CV events

· Myocardial toxicity

· Pharmacogenomics and drug-induced CV injury

· How can we practically assess the negative inotropic potential of new drugs?

· Anticoagulant safety—how to measure it?

Evolving Science of QT/Arrhythmia Assessment

Additional Information

		Cardiovascular Safety in Drug Development: QT, Arrhythmias, Thrombosis, and Bleeding

		AllConferences.com > Health > Pharmacy
Advanced Search
Submit a Conference
Linking Information
Advertise	About Us

See Also:
AIDS Alternative Beauty Child Dentistry Disabilities Education Environmental Fitness	Insurance Long_Term Medicine Mens_Health Mental Neurology Nursing Nutrition Physiology	Professions Public_Health Senior Services Teen Veterinary